Teva gets FDA nod for generic version of Novo's weight loss drug

6 hours ago 1

Teva Pharmaceuticals (NYSE:TEVA) said that the U.S. FDA approved its generic version of Novo Nordisk's (NVO) Saxenda (liraglutide injection), a GLP-1 weight loss drug.
“With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the